Eli Lilly ramps up its fight against imitation weight-loss drugs
The maker of blockbuster appetite-suppressing drugs Mounjaro and Zepbound is seeking to end a regulatory designation that has allowed cheaper, off-brand versions to flourish.
View original article
Contributor: Daniel Gilbert
